Senseonics is a medical technology company developing and commercializing Eversense, a long-term implantable continuous glucose monitoring (CGM) system for people with diabetes that measures glucose levels for 6 to 12 months—substantially longer than traditional non-implantable systems. The Eversense system comprises a subcutaneous sensor, a removable rechargeable transmitter worn on the skin, and a mobile app providing real-time glucose readings and alerts, with key advantages including extended duration, high accuracy, and continuous support. The company generates revenue from sales of sensor packs, transmitter packs, and insertion and removal procedure fees, selling through distributors and healthcare provider networks to patients and healthcare providers globally; reimbursement from third-party payors and government programs is critical to its business model. Senseonics competes against larger, well-capitalized companies such as Dexcom, Medtronic, and Abbott in the large and growing diabetes care market, differentiated by its superior sensor duration and accuracy in hypoglycemic ranges.